Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

Group 1 - Neurocrine Biosciences reported fourth-quarter adjusted EPS of $1.69, exceeding last year's$1.54 and beating the consensus of $1.56 [1] - The company reported sales of$627.7 million, up from $515.2 million a year ago, but missed the consensus of$628.99 million [1] - Ingrezza's fourth-quarter net product sales were $615 million, reflecting a 23$2 million, following initial pharmacy orders after FDA approval in December 2024 [2] - Neurocrine expects Ingrezza net product sales for 2025 to be between $2.5 billion and$2.6 billion [2] - William Blair views Ingrezza's 2025 revenue guidance as slightly conservative compared to their estimate of $2.60 billion and the Street estimate of$2.67 billion [3] Group 3 - Analyst Myles Minter considers Ingrezza the gold-standard pharmacotherapy for tardive dyskinesia due to its dosing convenience and lack of severe FDA warnings [4] - Ingrezza has 14 years of potential patent protection, indicating a long growth trajectory despite near-term competitive pressures [5] - Neurocrine's stock price decreased by 1.91% to $121.98, with various analysts maintaining or adjusting their ratings and price targets [5]